Session describes the logistics behind radiopharmaceutical therapy (RPT) administration, starting with drug receipt, preparation, infusion, and finishing with patient release.  The session highlights the role of the qualified medical physicist (QMP) in ensuring safety, quality, and regulatory com

This session explores two essential components of a successful RPT program: authorized user credentialing process and structured training for medical physicists. It includes a step-by-step overview of the regulatory pathway for obtaining AU status, including required training and documentation.

This session offers a comprehensive and candid review of the evolution, current impact, and future direction of radiotheranostics, with a particular focus on PSMA targeted imaging and therapy in prostate cancer.

This session addresses the initial steps required for building a radiopharmaceutical program. Crucial to starting a program is understanding the business case, which includes understanding the potential referral stream, reimbursement, personnel, space, and equipment costs to start a program.

This keynote examined how leadership, culture, and aligned incentives can accelerate medical innovation, drawing lessons from the rapid development of COVID 19 vaccines and their application to radiopharmaceutical therapies (RPTs).

Radiopharmaceutical therapies (RPTs) are increasingly utilized for treatment of prostate, neuroendocrine, thyroid and other cancers.

This journal activity provides practitioners with additional knowledge to aid making treatment decisions about the use of proton therapy for intracranial tumors, and to effectively counsel patients considering proton therapy about the risks to short-term cognition.